Antibodies generated from only two vaccine doses offer less protection against the Omicron variant
News
Beximco Pharma to manufacture molnupiravir for COVID-19
The drug received conditional marketing authorisation in the UK from the MHRA in November
New AstraZeneca treatment for rare cancer reduces risk of death
Imfinzi has shown improvements in the overall survival of patients with biliary tract cancer
NICE moves: increased accessibility and flexibility for health tech
NICE also aims to make strides in digital, genomic and antimicrobial technologies
Air of optimism surrounds lung cancer vaccine
Cancer Research UK announces clinical trial for most common type of lung cancer
First-of-its-kind NHS gene pilot takes off
The NHS launches world-first study investigating genetic testing for common diseases
CDI prevention reaches date with destiny
Clinical stage outfit, Destiny Pharma, provides a positive summary of the year ahead
Poolbeg Pharma dives into nasally administered antivirals
If we have learnt anything from the last two years, it’s that virus protection is not to be sniffed at
Gates Foundation supports HIV and malaria research
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation
While Omicron continues to dominate across the world, COVID-19 travel requirements remain
Djokovic drama causes a racket: so how would the UK respond?
Collaborative research approach set to accelerate treatment of Alport syndrome
Despite diagnosis and treatment options improving for the rare kidney condition, further action is urgently required.
New study finds AstraZeneca booster generates higher antibodies against Omicron
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.
Liverpool CCG and Community Pharmacy Liverpool launch FebriDx point-of-care test
The test is hoped to provide patients with a more convenient means of access to treatment for respiratory issues.
UKHSA estimates one in seven still infectious after five day COVID-19 isolation
Under current guidelines, individuals that test positive for COVID-19 may be able to leave self-isolation after 7 days if certain conditions are met.
Oxford joins consortium to advance quantum drug discovery
The partnership between Oxford University and SEEQC promises to accelerate the use of quantum computing within pharmaceutical research in order to reduce the development time required for drug production worldwide.
